Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Tryp Therapeutics Inc (TRYP.CN)

Tryp Therapeutics Inc (TRYP.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 17,175
  • Shares Outstanding, K 95,419
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,255 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.78
Trade TRYP.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings -0.01 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.125 +60.00%
on 07/15/22
0.210 -4.76%
on 08/04/22
+0.080 (+66.67%)
since 07/11/22
3-Month
0.055 +263.64%
on 05/31/22
0.210 -4.76%
on 08/04/22
+0.115 (+135.29%)
since 05/11/22
52-Week
0.055 +263.64%
on 05/31/22
0.550 -63.64%
on 08/27/21
-0.330 (-62.26%)
since 08/11/21

Most Recent Stories

More News
TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

/CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based...

TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)
Stocks in play: Tryp Therapeutics Inc

Announced a non-brokered private placement to its co-Founder and Executive Director, William J. Garner, ...

TRYP.CN : 0.200 (+11.11%)
Stocks in play: Tryp Therapeutics Inc

Announced today that it has received confirmation from the U.S. Food and Drug Administration that its ...

TRYP.CN : 0.200 (+11.11%)
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration...

TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)  is advancing toward the launch of four phase 2a studies of its two novel drug candidates, TRP-8802 and TRP-8803, for treating fibromyalgia, phantom limb pain,...

TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways

Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass...

ATAI : 4.41 (-5.77%)
CMPS : 17.46 (-11.51%)
TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)
FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process

Psychedelic drug medical research firm Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has received final U.S. Food and Drug Administration (“FDA”) approval to get under way with its planned clinical...

TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)
Missed Eating Disorder Diagnoses in Men Are on the Rise

Eating disorders are severe mental and physical illnesses that encompass  damaging relationships with  body image, exercise, eating and food. Research has found that behaviors that are linked to eating...

TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the...

TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation...

TRYP.CN : 0.200 (+11.11%)
TRYPF : 0.1470 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.180
2nd Resistance Point 0.180
1st Resistance Point 0.180
Last Price 0.200
1st Support Level 0.180
2nd Support Level 0.180
3rd Support Level 0.180

See More

52-Week High 0.550
Fibonacci 61.8% 0.361
Fibonacci 50% 0.303
Fibonacci 38.2% 0.244
Last Price 0.200
52-Week Low 0.055

See More

Business Summary

Tryp Therapeutics Inc is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company's main development program PFN program is designed to treat neuropsychiatric disorders through the dosing...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar